{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/how-this-topic-was-developed/stakeholder-engagement/","result":{"pageContext":{"chapter":{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement","depth":2,"htmlHeader":"<!-- begin field 27e638e8-4227-4d6f-95c2-a7f20176b5d9 --><h2>Stakeholder engagement</h2><!-- end field 27e638e8-4227-4d6f-95c2-a7f20176b5d9 -->","summary":null,"htmlStringContent":"<!-- begin item 195d3a45-227f-4897-882c-a7f20174d91e --><!-- begin field b4c010ae-6997-4925-be6f-a7f20176b5d9 --><h2>Our policy</h2><!-- end field b4c010ae-6997-4925-be6f-a7f20176b5d9 --><!-- begin field 65228008-bf20-4d02-a7f1-a7f20176b5d9 --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field 65228008-bf20-4d02-a7f1-a7f20176b5d9 --><!-- begin field fb676d55-53d2-4b90-b548-a7f20176b5d9 --><h2>Principles of the consultation process</h2><!-- end field fb676d55-53d2-4b90-b548-a7f20176b5d9 --><!-- begin field 46f7f531-e28a-4d8b-a365-a7f20176b5d9 --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field 46f7f531-e28a-4d8b-a365-a7f20176b5d9 --><!-- begin field b4375228-2c33-433b-bb1c-a7f20176b5d9 --><h2>Stakeholders</h2><!-- end field b4375228-2c33-433b-bb1c-a7f20176b5d9 --><!-- begin field 50567853-f023-45a8-af57-a7f20176b5d9 --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"ade4a01a-a1aa-48a6-b16b-a991017eb1a5\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"75348fd5-c6fb-43fe-af46-a991017eb269\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies (for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field 50567853-f023-45a8-af57-a7f20176b5d9 --><!-- begin field fa6536b9-cd7b-4243-93a2-a7f20176b5d9 --><h2>Patient engagement</h2><!-- end field fa6536b9-cd7b-4243-93a2-a7f20176b5d9 --><!-- begin field 96f5674c-2931-43b7-b66c-a7f20176b5d9 --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field 96f5674c-2931-43b7-b66c-a7f20176b5d9 --><!-- end item 195d3a45-227f-4897-882c-a7f20174d91e -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}